CL2023002676A1 - Formas cristalinas de (4s)-24-cloro-4-etil-73-fluoro-35-metoxi-32,5-dioxo-14-(trifluoro-metil)-32h-6-aza- 3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida - Google Patents

Formas cristalinas de (4s)-24-cloro-4-etil-73-fluoro-35-metoxi-32,5-dioxo-14-(trifluoro-metil)-32h-6-aza- 3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida

Info

Publication number
CL2023002676A1
CL2023002676A1 CL2023002676A CL2023002676A CL2023002676A1 CL 2023002676 A1 CL2023002676 A1 CL 2023002676A1 CL 2023002676 A CL2023002676 A CL 2023002676A CL 2023002676 A CL2023002676 A CL 2023002676A CL 2023002676 A1 CL2023002676 A1 CL 2023002676A1
Authority
CL
Chile
Prior art keywords
dibenzeneheptaphane
aza
dioxo
carboxamide
triazole
Prior art date
Application number
CL2023002676A
Other languages
English (en)
Inventor
Michal Sowa
Britta Olenik
Guillaume Levilain
Tia Jacobs
Franco Rubino
Krischan Ziem
Susanne Röhrig
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of CL2023002676A1 publication Critical patent/CL2023002676A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a formas cristalinas de (4S)–2 4–cloro–4–etil– 7 3–fluoro–3 5–metoxi–3 2 ,5–dioxo–1 4–(trifluorometil)–3 2H–6–aza–3(4,1)–piridina– 1(1)–[1,2,3]triazola–2(1,2),7(1)–dibencenaheptafano–7 4–carboxamida que son la modificación cristalina I y la modificación cristalina II, a procesos para su preparación, a composiciones farmacéuticas que las comprenden y a su uso en el control de trastornos.
CL2023002676A 2021-03-09 2023-09-07 Formas cristalinas de (4s)-24-cloro-4-etil-73-fluoro-35-metoxi-32,5-dioxo-14-(trifluoro-metil)-32h-6-aza- 3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida CL2023002676A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21161489 2021-03-09

Publications (1)

Publication Number Publication Date
CL2023002676A1 true CL2023002676A1 (es) 2024-02-09

Family

ID=74867465

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002676A CL2023002676A1 (es) 2021-03-09 2023-09-07 Formas cristalinas de (4s)-24-cloro-4-etil-73-fluoro-35-metoxi-32,5-dioxo-14-(trifluoro-metil)-32h-6-aza- 3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida

Country Status (15)

Country Link
US (1) US20240174633A1 (es)
EP (1) EP4304714A1 (es)
JP (1) JP2024508971A (es)
KR (1) KR20230155505A (es)
CN (1) CN117015535A (es)
AU (1) AU2022235150A1 (es)
BR (1) BR112023016298A2 (es)
CA (1) CA3212645A1 (es)
CL (1) CL2023002676A1 (es)
CO (1) CO2023011801A2 (es)
DO (1) DOP2023000170A (es)
IL (1) IL305231A (es)
MX (1) MX2023010614A (es)
TW (1) TW202302561A (es)
WO (1) WO2022189279A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023174399A1 (zh) * 2022-03-18 2023-09-21 苏州晶云药物科技股份有限公司 取代的氧代吡啶类衍生物的晶型及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168098A1 (en) 2015-04-16 2016-10-20 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
HUE058796T2 (hu) 2018-03-15 2022-09-28 Bayer Ag Két 4-{[(2S)-2-{4-[5-klór-2-(1H-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1 (2H)-il}butanoil]amino}-2-fluorbenzamid származék elõállítási eljárása
WO2020126682A1 (en) * 2018-12-17 2020-06-25 Bayer Aktiengesellschaft Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications
BR112021009435A2 (pt) 2018-12-21 2021-08-17 Bayer Aktiengesellschaft derivados de oxopiridina substituída

Also Published As

Publication number Publication date
DOP2023000170A (es) 2023-09-29
CN117015535A (zh) 2023-11-07
AU2022235150A1 (en) 2023-08-31
CO2023011801A2 (es) 2023-09-18
EP4304714A1 (en) 2024-01-17
TW202302561A (zh) 2023-01-16
WO2022189279A1 (en) 2022-09-15
MX2023010614A (es) 2023-09-19
CA3212645A1 (en) 2022-09-15
BR112023016298A2 (pt) 2023-10-03
KR20230155505A (ko) 2023-11-10
JP2024508971A (ja) 2024-02-28
US20240174633A1 (en) 2024-05-30
IL305231A (en) 2023-10-01

Similar Documents

Publication Publication Date Title
CL2023002676A1 (es) Formas cristalinas de (4s)-24-cloro-4-etil-73-fluoro-35-metoxi-32,5-dioxo-14-(trifluoro-metil)-32h-6-aza- 3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
UY28895A1 (es) Derivados de tetrahidronaftiridina
DOP2018000237A (es) Forma polimorfa de n–{6–(2–hidroxipropan–2–il)–2–[2–(metilsulfonil)etil]–2h–indazol–5–il}–6–(trifluorometil)piridin–2–carboxamida
UY27659A1 (es) Derivados de nicotinamida útiles como inhibidores de pde4
BRPI0408681A (pt) compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
BRPI0410454A (pt) composições e compostos imunossupressores
CR20200554A (es) Derivados sustituidos de la carboxamida dihidropirazolo pirazina
EA200800162A1 (ru) Новые фармацевтические композиции с замедленным высвобождением и способы их получения
BRPI0606132A2 (pt) formas cristalinas de docetaxel e processos para seu preparo
ATE411296T1 (de) Imidazolinderivate mit cb1-antagonistischer wirkung
ATE534292T1 (de) Spiroverbindungen und anwendungsverfahren dafür
UY39484A (es) Inhibidores de interleucina-17
MY196791A (en) New tetrahydropyrimidodiazepin and dihydropyridodiazepin compounds for treating pain and pain related conditions
CY1110711T1 (el) Παραγωγα πυραζολο [3,4-d]αζεπινης ως ανταγωνιστες ισταμινης η3
CL2023002665A1 (es) Formas de dosificación farmacéuticas que comprenden (4s)–24–cloro–4–etil–73–fluoro–35–metoxi– 32,5–dioxo–14–(trifluorometil)–32h–6–aza–3(4,1)–piridina–1(1)–[1,2,3]triazola–2 (1,2),7(1)–dibencenaheptafano–74–carboxamida
TW200505356A (en) Method of pulverizing non-sugar component and pulverizing base
DK1383756T3 (da) Cumarinderivater til anvendelse som antikoagulanter
UY28247A1 (es) Compuestos de benzopirano para uso en el tratamiento y la prevención de afecciones relacionadas con la inflamación.
EA202191378A1 (ru) Активные сложноэфирные производные тестостерона, их композиции и применения
ECSP003707A (es) Diazepanes
BR0208038A (pt) Uso de um ou mais componentes saudáveis e método para a administração de um componente saudável.
CY1125187T1 (el) Εκχυλισματα φυτων εμπλουτισμενα με παραγωγα ιπολαμιιδης ως ανοσοκατασταλτικα για τη θεραπεια ανοσολογικων διαταραχων
WO2008012413A3 (fr) Derives de pyrimidinone et leur utilisation comme medicament
WO2010064792A3 (ko) 푸코이단을 함유하는 골 형성 촉진 및 활성용 약학 조성물